| Literature DB >> 33654169 |
Yueshuo Li1,2,3, Feng Shi1,2,3, Jianmin Hu1,2,3, Longlong Xie1,2,3, Lin Zhao1,2,3, Min Tang1,2,3, Xiangjian Luo1,2,3, Mao Ye4, Hui Zheng5, Min Zhou1,2,3, Na Liu1,2,3, Ann M Bode6, Jia Fan7, Jian Zhou7, Qiang Gao7, Shuangjian Qiu7, Weizhong Wu7, Xin Zhang8, Weihua Liao9, Ya Cao10,11,12,13,14,15.
Abstract
p18 is a key negative regulator of cell cycle progression and mediates cell cycle arrest at the G1/S phase. Ubiquitination is the prime mechanism in regulating p18 protein abundance. However, so far no post- translational regulator, especially DUBs, has been identified to regulate the protein stability of p18. In this paper, we identified CYLD as a deubiquitinase of p18, which binds to and removes the K48-linked polyubiquitylation chains conjugated onto p18, thus stabilizing the p18 protein. Loss of CYLD causes the degradation of p18 and induces the G1/S transition. Epstein-Barr virus (EBV), is the human oncovirus etiologically linked to nasopharyngeal carcinoma (NPC). Here we found that EBV drives a replication passive environment by deregulating the CYLD-p18 axis. Functionally, CYLD inhibits cell proliferation and tumorigenesis through p18 in vivo. Restoring CYLD prevents EBV induced viral replication and tumor growth. Collectively, our results identify CYLD directly stabilizes p18 to regulate the cellular G1/S transition. The reconstitution of CYLD-p18 axis could be a promising approach for EBV-positive cancer therapy.Entities:
Year: 2021 PMID: 33654169 DOI: 10.1038/s41698-021-00153-8
Source DB: PubMed Journal: NPJ Precis Oncol ISSN: 2397-768X